These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
192 related items for PubMed ID: 11137257
1. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine. Watanabe M, Nagai M, Funaishi K, Endoh M. Vaccine; 2000 Dec 08; 19(9-10):1199-203. PubMed ID: 11137257 [Abstract] [Full Text] [Related]
2. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins. Watanabe M, Funaishi K, Takeo T, Endoh M. Vaccine; 2000 Dec 08; 19(9-10):1204-10. PubMed ID: 11137258 [Abstract] [Full Text] [Related]
7. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Belloni C, De Silvestri A, Tinelli C, Avanzini MA, Marconi M, Strano F, Rondini G, Chirico G. Pediatrics; 2003 May 08; 111(5 Pt 1):1042-5. PubMed ID: 12728086 [Abstract] [Full Text] [Related]
8. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines. Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, Mertsola J, He Q. J Immunol Methods; 2014 Jun 08; 408():142-8. PubMed ID: 24925807 [Abstract] [Full Text] [Related]
9. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. He Q, Tran Minh NN, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. Infect Immun; 1998 Aug 08; 66(8):3796-801. PubMed ID: 9673264 [Abstract] [Full Text] [Related]
10. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines. Boros CA, Hanlon M, Gold MS, Roberton DM. Vaccine; 2001 May 14; 19(25-26):3537-42. PubMed ID: 11348721 [Abstract] [Full Text] [Related]
12. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model. Watanabe M, Komatsu E, Abe K, Iyama S, Sato T, Nagai M. Vaccine; 2002 Jan 31; 20(9-10):1429-34. PubMed ID: 11818163 [Abstract] [Full Text] [Related]
14. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers. Littmann M, Hülsse C, Riffelmann M, Wirsing von König CH. Vaccine; 2008 May 02; 26(19):2344-9. PubMed ID: 18396360 [Abstract] [Full Text] [Related]
15. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Ausiello CM, Urbani F, La Sala A, Lande R, Piscitelli A, Cassone A. Dev Biol Stand; 1997 May 02; 89():315-20. PubMed ID: 9272365 [Abstract] [Full Text] [Related]
19. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model. Kwon HJ, Han SB, Kim BR, Kang KR, Huh DH, Choi GS, Ahn DH, Kang JH. BMC Infect Dis; 2017 Apr 04; 17(1):247. PubMed ID: 28376777 [Abstract] [Full Text] [Related]
20. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Knight JB, Huang YY, Halperin SA, Anderson R, Morris A, Macmillan A, Jones T, Burt DS, Van Nest G, Lee SF. Clin Exp Immunol; 2006 Jun 04; 144(3):543-51. PubMed ID: 16734625 [Abstract] [Full Text] [Related] Page: [Next] [New Search]